Developing a platform for early cancer detection using DNA analysis
Official title: A Prospective, Multi-center Clinical Study to Establish Multi-Cancer Early Detection Platform Through the Analysis of Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy Volunteers.
Run by Yonsei University · NCT06231953 · Data updated 2026-11-12
This study is testing a new way to detect cancer early by analyzing DNA from blood samples of both cancer patients and healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | Yonsei University Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | October 13, 2022 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | January 30, 2024 |
| Trial ID | NCT06231953 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 19 years or older diagnosed with stages 1 to 4 of solid tumors or healthy volunteers scheduled for cancer screening.
✕Probably not a fit
Patients with a history of certain infections, severe mental disorders, or multiple primary cancers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a Multi-Cancer Early Detection (MCED) platform by analyzing whole genome sequencing of circulating tumor DNA from both cancer patients and healthy volunteers. The study will enroll 4,000 participants across multiple clinical institutions in South Korea. Blood samples will be collected from individuals diagnosed with invasive cancers and healthy volunteers undergoing cancer screening. The data will be processed using machine learning techniques to enhance early cancer detection capabilities.
Why it matters
Potential benefit: If successful, this study could significantly improve early cancer detection, leading to better treatment outcomes for patients.
How similar studies have gone: Other studies utilizing similar approaches in early cancer detection have shown promising results, indicating potential for success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 19 years or older * Subjects who have been diagnosed with stages 1 to 4 of solid tumor or healthy volunteers who have scheduled a cancer screening examination * Subjects who have agreed to provide clinical information and blood samples * Subjects who have agreed for the storage and secondary use of residual blood samples for research * Subjects who have understood the study and are able to provide a written informed consent Exclusion Criteria: * Subjects who are not appropriate for the study because of intellectual disabilities or severe mental disorders * Subjects with a history of HIV, HTLV, or Syphilis infection * Subjects with primary site unknown cancer or synchronous or metachronous double primary cancers * Subjects who have diagnosed with any other malignant tumor within the past 5 years (except for cured non-melanoma skin cancer, in situ cancer, or thyroid cancer)
Where it's running
-
Yonsei Cancer Center, Yonsei Univ. College of Medicine
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Joohyuk Sohn — Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine
- Study coordinator: Joohyuk Sohn
- Email: oncosohn@yuhs.ac
- Phone: +82-2-2228-8135
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing advice on moderate drinking versus abstention for health outcomes
This study is testing whether giving advice on moderate drinking or complete abstention is better for the health of adults over 50 in Spain.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
-
SVF cellular mix, secretome, and knee response in osteoarthritis
This study tests the cellular composition and secretome of research-only adipose-derived SVF in adults with knee OA who are already planned to receive an autologous SVF injection as part of their care.
-
2-mm subchondral drilling vs sequential 4-mm and 2-mm drilling during CARTISTEM implantation for knee cartilage defects
This study tests whether drilling the knee with a 2-mm drill alone works as well as sequential 4-mm then 2-mm drilling when combined with CARTISTEM treatment for medial knee cartilage defects.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.